Considering the role of CETP in RCT, which favors transfer of cholesterol from HDL to LDL, it was thought that a pharmacological action against this enzyme could reduce the risk of atherosclerosis, and synthetic inhibitors were developed to restore a favourable lipoprotein profile by increasing HDL-C concentration and lowering LDL-C concentration. The gene discussed is CETP; the disease is atherosclerosis.